Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Raw Materials (2016 - 2020)

United Therapeutics (UTHR) has disclosed Raw Materials for 11 consecutive years, with $20.1 million as the latest value for Q1 2020.

  • Quarterly Raw Materials fell 9.87% to $20.1 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $20.1 million through Mar 2020, down 9.87% year-over-year, with the annual reading at $21.1 million for FY2019, 13.17% down from the prior year.
  • Raw Materials hit $20.1 million in Q1 2020 for United Therapeutics, down from $21.1 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $29.1 million in Q2 2017 to a low of $19.3 million in Q3 2019.
  • Historically, Raw Materials has averaged $24.4 million across 5 years, with a median of $24.8 million in 2016.
  • Biggest five-year swings in Raw Materials: increased 17.34% in 2017 and later dropped 25.77% in 2019.
  • Year by year, Raw Materials stood at $25.4 million in 2016, then grew by 9.84% to $27.9 million in 2017, then decreased by 12.9% to $24.3 million in 2018, then decreased by 13.17% to $21.1 million in 2019, then fell by 4.74% to $20.1 million in 2020.
  • Business Quant data shows Raw Materials for UTHR at $20.1 million in Q1 2020, $21.1 million in Q4 2019, and $19.3 million in Q3 2019.